Dyne Therapeutics Files Current Report

Ticker: DYN · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1818794

Dyne Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyDyne Therapeutics, INC. (DYN)
Form Type8-K
Filed DateJan 10, 2025
Risk Levellow
Pages8
Reading Time9 min
Key Dollar Amounts$0.0001, $642 million
Sentimentneutral

Sentiment: neutral

Topics: corporate-filing, regulatory

Related Tickers: DYN

TL;DR

Dyne Therapeutics (DYN) filed a routine 8-K on Jan 10, 2025, confirming its Nasdaq listing and corporate details.

AI Summary

Dyne Therapeutics, Inc. filed an 8-K on January 10, 2025, reporting its status as a Delaware corporation with its principal executive offices in Waltham, Massachusetts. The company's common stock trades under the ticker DYN on the Nasdaq Global Select Market. This filing serves as a current report, indicating ongoing corporate activities and disclosures.

Why It Matters

This 8-K filing is a routine disclosure that confirms Dyne Therapeutics' operational status and stock exchange listing, providing essential information for investors and regulatory bodies.

Risk Assessment

Risk Level: low — This filing is a standard corporate disclosure and does not contain new material information that would inherently increase risk.

Key Players & Entities

FAQ

What is the primary purpose of this Form 8-K filing for Dyne Therapeutics, Inc.?

The primary purpose of this Form 8-K filing is to serve as a Current Report, indicating that Dyne Therapeutics, Inc. is disclosing information about significant events or corporate changes as required by the Securities Exchange Act of 1934.

On what date was the earliest event reported in this filing?

The earliest event reported in this filing occurred on January 10, 2025.

In which U.S. state is Dyne Therapeutics, Inc. incorporated?

Dyne Therapeutics, Inc. is incorporated in Delaware.

What is the trading symbol for Dyne Therapeutics, Inc.'s common stock, and on which exchange is it listed?

The trading symbol for Dyne Therapeutics, Inc.'s common stock is DYN, and it is listed on the Nasdaq Global Select Market.

Where are Dyne Therapeutics, Inc.'s principal executive offices located?

Dyne Therapeutics, Inc.'s principal executive offices are located at 1560 Trapelo Road, Waltham, Massachusetts, 02451.

Filing Stats: 2,361 words · 9 min read · ~8 pages · Grade level 13.1 · Accepted 2025-01-10 06:56:30

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated January 10, 2025. 99.2 Presentation, dated January 10, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DYNE THERAPEUTICS, INC. Date: January 10, 2025 By: /s/ John G. Cox Name: John G. Cox Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing